Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma Xavier GarcÃa del MuroEnrique GallardoDaniel Castellano Review Article 16 February 2014 Pages: 1095 - 1107
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers Robert C. ShumakerMeijian ZhouBorje Darpo Original Article 23 March 2014 Pages: 1109 - 1117
An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma Mona DarwishJohn M. BurkeMary Bond Original Article Open access 28 March 2014 Pages: 1119 - 1127
Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails Weiheng HuJian FangJindi Han Original Article 21 April 2014 Pages: 1129 - 1136
Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993) Joel M. ReidSarah A. BuhrowMatthew M. Ames Original Article 24 April 2014 Pages: 1137 - 1146
Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy Takahide TaguchiGoshi NishimuraNobuhiko Oridate Original Article 23 March 2014 Pages: 1147 - 1154
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis Yan WangYi-yi YuTian-shu Liu Original Article Open access 21 April 2014 Pages: 1155 - 1161
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy Faruk TasSenem KarabulutDerya Duranyildiz Original Article 20 March 2014 Pages: 1163 - 1171
Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors Fangfang LvJunning CaoJin Li Original Article 23 March 2014 Pages: 1173 - 1179
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy Jessica MwinyiKerstin VokingerAndreas Trojan Original Article 29 March 2014 Pages: 1181 - 1188
Pharmacokinetics of pazopanib administered in combination with bevacizumab Diane-Charlotte ImbsSylvie NégrierEtienne Chatelut Original Article 06 April 2014 Pages: 1189 - 1196
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients Katherine M. SlusarzVanessa L. MerkerScott R. Plotkin Original Article 08 April 2014 Pages: 1197 - 1204
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors Ramon SalazarSerafin MoralesAntonio Llombart Original Article 18 April 2014 Pages: 1205 - 1215
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease Moon Ki ChoiJung Yong HongJin Seok Ahn Original Article 03 April 2014 Pages: 1217 - 1225
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck Vassiliki SalouraEzra E. W. CohenThomas C. Gauler Original Article 09 April 2014 Pages: 1227 - 1239
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors Pierre Maison-BlancheShaker DakhilJames L. Wade Original Article 10 April 2014 Pages: 1241 - 1252
Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial Takashi TsuchiyaSotaro SadahiroShigetoyo Saji Original Article Open access 18 April 2014 Pages: 1253 - 1261
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells Sudipa S. RoyNameer B. KirmaJoseph K. Agyin Original Article 12 April 2014 Pages: 1263 - 1271
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells Kaamar AzijliIngrid A. M. van RoosmalenFrank A. E. Kruyt Original Article 18 April 2014 Pages: 1273 - 1283
Pharmacokinetics and exposure–effect relationships of capecitabine in elderly patients with breast or colorectal cancer Z. Daher AbdiS. Lavau-DenesA. Rousseau Original Article 07 May 2014 Pages: 1285 - 1293
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004) Masanori ToyodaTetsuo AjikiTatsuya Ioka Clinical Trial Report Open access 11 March 2014 Pages: 1295 - 1301
Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction L. L. KrensJ. M. BaasH. Gelderblom Short Communication 06 April 2014 Pages: 1303 - 1306
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase C. A. FernandezE. StewartP. K. Campbell Short Communication 27 April 2014 Pages: 1307 - 1313
